Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies [0.03%]
Lazertinib的心脏安全评估：来自EGFR突变阳性晚期NSCLC患者的临床前研究的结果
Seong Bok Jang,Kyeong Bae Kim,Sujin Sim et al.
Seong Bok Jang et al.
Introduction: Lazertinib is a potent, irreversible, brain-penetrant, mutant-selective, and wild-type-sparing third-generation EGFR tyrosine kinase inhibitor (TKI), creating a wide therapeutic index. Cardiovascular adverse...
[This corrects the article DOI: 10.1016/j.jtocrr.2020.100035.]. © 2021 The Authors.
Published Erratum
JTO clinical and research reports. 2021 Feb 19;2(4):100158. DOI:10.1016/j.jtocrr.2021.100158 2021
[This corrects the article DOI: 10.1016/j.jtocrr.2020.100022.]. © 2021 The Author.
Published Erratum
JTO clinical and research reports. 2021 Mar 20;2(4):100168. DOI:10.1016/j.jtocrr.2021.100168 2021
SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report [0.03%]
小细胞癌，副肿瘤性皮肌炎，转录中介因子1-γ阳性及其编码基因点突变一例报告
Johnathan Arnon,Anna Elia,Yuval Nevo et al.
Johnathan Arnon et al.
SCLC is frequently associated with paraneoplastic syndromes, including dermatomyositis. Patients with malignancy-associated dermatomyositis express a specific autoantibody pattern usually positive for anti-transcription intermediary factor ...
First-in-Human Segmental Esophageal Reconstruction Using a Bioengineered Mesenchymal Stromal Cell-Seeded Implant [0.03%]
使用生物工程间充质基质细胞植入物进行首例人体食管节段重建
Johnathon M Aho,Saverio La Francesca,Scott D Olson et al.
Johnathon M Aho et al.
Introduction: Resection and reconstruction of the esophagus remains fraught with morbidity and mortality. Recently, data from a porcine reconstruction model revealed that segmental esophageal reconstruction using an autol...
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis [0.03%]
PD-1抑制剂与PD-L1抑制剂联合化疗作为晚期NSCLC一线治疗的系统评价和Meta分析
Alessandro Di Federico,Andrea De Giglio,Claudia Parisi et al.
Alessandro Di Federico et al.
Introduction: The addition of programmed cell death protein-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors to first-line chemotherapy (CT) improved the outcomes of advanced NSCLC. Nonetheless, no direct comparis...
Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report [0.03%]
KRAS G12C突变型NSCLC中司美替尼可能诱发重度免疫检查点抑制剂肝炎的病例报告
Parvin Begum,Robert D Goldin,Lucia A Possamai et al.
Parvin Begum et al.
Sotorasib is a first-in-class small molecule that irreversibly inhibits KRAS G12C, locking it in an inactive state, inhibiting oncogenic signaling, and inducing a proinflammatory microenvironment. Here, we report the first case of life-thre...
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors [0.03%]
厄洛替尼联合Xentuzumab(BI 836845)用于EGFR酪氨酸激酶抑制剂治疗后进展的EGFR突变阳性NSCLC的1b期开放标签试验
Keunchil Park,Daniel Shao Weng Tan,Wu-Chou Su et al.
Keunchil Park et al.
Introduction: Insulin-like growth factor signaling has been implicated in acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. This phase 1 trial (NCT02191891) investigated the combination of xentuzumab...
A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood [0.03%]
使用外周血中的循环肿瘤DNA进行EGFR T790M突变检测的全加拿大验证研究
Shamini Selvarajah,Sophie Plante,Marsha Speevak et al.
Shamini Selvarajah et al.
Introduction: Genotyping circulating tumor DNA (ctDNA) is a promising noninvasive clinical tool to identify the EGFR T790M resistance mutation in patients with advanced NSCLC with resistance to EGFR inhibitors. To facilit...
Increasing Heart Dose Reduces Overall Survival in Patients Undergoing Postoperative Radiation Therapy for NSCLC [0.03%]
接受术后放射治疗的NSCLC患者的射线剂量增加会减少总体生存率
Annemarie F Shepherd,Anthony F Yu,Michelle Iocolano et al.
Annemarie F Shepherd et al.
Introduction: Given the concern for cardiopulmonary toxicity in patients with NSCLC undergoing postoperative radiation therapy (PORT), the purpose of this study was to evaluate the association between heart dose and overa...